

1/3

SEQUENCE LISTING

<110> OSCIENT PHARMACEUTICALS CORPORATION

<120> METHOD OF SYNTHESIZING AND PURIFYING DKK PROTEINS AND
DKK PROTEINS OBTAINED THEREBY

<130> 032796-247 (WO)

<140> PCT/US05/010001

<141> 2005-03-23

<150> 60/555,406

<151> 2004-03-23

<160> 5

<170> PatentIn Ver. 3.3

<210> 1

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 1

ttttttggat ccgccaccat gatggctctg ggcgcag

37

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 2

tttttttcta gagtgtctct gacaagtgtg

30

<210> 3

<211> 21

<212> PRT

<213> Homo sapiens

<400> 3

Arg Ile Gln Lys Asp His His Gln Ala Ser Asn Ser Ser Arg Leu His
1 5 10 15

Thr Cys Gln Arg His
20

<210> 4
 <211> 879
 <212> DNA
 <213> Homo sapiens

<400> 4
 atgatggctc tggg'gcgcagc gggagctacc cgggtcctttg tgcgatggg agcggcggct 60
 ctccggcggcc accctctgct gggagtgagc gccaccttga actcgggttct caattccaac 120
 gctatcaaga acctgcccc accgctgggc ggcgctgcgg ggcacccagg ctctgcagtc 180
 agcgcgcgcgc cggaatcct gtaccggggc gggaataagt accagaccat tgacaactac 240
 cagccgtacc cgtgcgcaga ggacgaggag tgcggcactg atgagtactg cgctagtccc 300
 acccgcgag gggacgcggg cgtgcaaatac tgtctcgct gcaggaagcg ccgaaaacgc 360
 tgcattgcgtc acgctatgtg ctgccccggg aattactgca aaaatggaat atgtgtgtct 420
 tctgatcaaa atcatttccg aggagaaatt gaggaacca tcaactgaaag ctttggtaat 480
 gatcatagca ccttggtatg gtattccaga agaaccacct tgtcttcaaa aatgtatcac 540
 accaaaggac aagaagggtc tgtttgtctc cggtcacag actgtgcctc aggattgtgt 600
 tgtgctagac acttctggtc caagatctgt aaacctgtcc tgaaagaagg tcaagtgtgt 660
 accaagcata ggagaaaagg ctctcatgga ctagaaatat tccagcgttg ttactgtgga 720
 gaaggtctgt cttgccggat acagaaagat caccatcaag ccagtaattc ttctaggctt 780
 cacacttgtc agagacactc tagagggcc ttcgaacaaa aactcatctc agaagaggat 840
 ctgaatatgc ataccggtca tcatcaccat caccattga 879

<210> 5
 <211> 292
 <212> PRT
 <213> Homo sapiens

<400> 5
 Met Met Ala Leu Gly Ala Ala Gly Ala Thr Arg Val Phe Val Ala Met
 1 5 10 15
 Val Ala Ala Ala Leu Gly Gly His Pro Leu Leu Gly Val Ser Ala Thr
 20 25 30
 Leu Asn Ser Val Leu Asn Ser Asn Ala Ile Lys Asn Leu Pro Pro Pro
 35 40 45
 Leu Gly Gly Ala Ala Gly His Pro Gly Ser Ala Val Ser Ala Ala Pro
 50 55 60
 Gly Ile Leu Tyr Pro Gly Gly Asn Lys Tyr Gln Thr Ile Asp Asn Tyr
 65 70 75 80
 Gln Pro Tyr Pro Cys Ala Glu Asp Glu Glu Cys Gly Thr Asp Glu Tyr
 85 90 95
 Cys Ala Ser Pro Thr Arg Gly Gly Asp Ala Gly Val Gln Ile Cys Leu
 100 105 110
 Ala Cys Arg Lys Arg Arg Lys Arg Cys Met Arg His Ala Met Cys Cys
 115 120 125
 Pro Gly Asn Tyr Cys Lys Asn Gly Ile Cys Val Ser Ser Asp Gln Asn
 130 135 140
 His Phe Arg Gly Glu Ile Glu Glu Thr Ile Thr Glu Ser Phe Gly Asn
 145 150 155 160

Asp	His	Ser	Thr	Leu	Asp	Gly	Tyr	Ser	Arg	Arg	Thr	Thr	Leu	Ser	Ser	165	170	175	
Lys	Met	Tyr	His	Thr	Lys	Gly	Gln	Glu	Gly	Ser	Val	Cys	Leu	Arg	Ser	180	185	190	
Ser	Asp	Cys	Ala	Ser	Gly	Leu	Cys	Cys	Ala	Arg	His	Phe	Trp	Ser	Lys	195	200	205	
Ile	Cys	Lys	Pro	Val	Leu	Lys	Glu	Gly	Gln	Val	Cys	Thr	Lys	His	Arg	210	215	220	
Arg	Lys	Gly	Ser	His	Gly	Leu	Glu	Ile	Phe	Gln	Arg	Cys	Tyr	Cys	Gly	225	230	235	240
Glu	Gly	Leu	Ser	Cys	Arg	Ile	Gln	Lys	Asp	His	His	Gln	Ala	Ser	Asn	245	250	255	
Ser	Ser	Arg	Leu	His	Thr	Cys	Gln	Arg	His	Ser	Arg	Gly	Pro	Phe	Glu	260	265	270	
Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	Asn	Met	His	Thr	Gly	His	His	275	280	285	
His	His	His	His													290			